2024
KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Perry J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelson T, Owen S, Mason W, Drappatz J, Blondin N, de Groot J. KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology 2024, 26: v5-v5. PMCID: PMC11485821, DOI: 10.1093/neuonc/noae144.013.Peer-Reviewed Original ResearchReal-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.
Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.Peer-Reviewed Original ResearchNon-small cell lung cancerDiagnosis of LMNational Comprehensive Cancer NetworkLeptomeningeal metastasesTumor cell assayPositive CTCsCerebrospinal fluidData cutoffOverall survivalNeurological symptomsAssessment of circulating tumor DNASensitivity of tumor cell detectionCTC assayManagement of leptomeningeal metastasisTime of data cutoffDiagnosis of leptomeningeal metastasisAssociated with longer survivalMedian overall survivalOmmaya reservoir placementEnumeration of circulating tumor cellsNegative cytology resultsCell lung cancerEffective treatment optionProgressive neurological symptomsInitiation of treatmentEvaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
de Groot J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelsen T, Owen S, Mason W, Drappatz J, Blondin N, Perry J. Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Journal Of Clinical Oncology 2024, 42: 2005-2005. DOI: 10.1200/jco.2024.42.16_suppl.2005.Peer-Reviewed Original ResearchOverall survivalHazard ratioBayesian predictive powerRandomized to CStage 1OS hazard ratioPromoter methylation statusSample sizeRecurrent glioblastomaIncreased OSEfficacy goalsInter-strand DNA crosslinksTargeted agentsRegistration trialsMultiple therapiesDNA double-strand breaksSubtypesDNA-targeting agentsPatient subtypesDouble-strand breaksGlioblastoma subtypesMethylation statusNDMRD
2023
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.Peer-Reviewed Original ResearchConceptsMedian overall survivalProgression-free survivalOverall survivalRecurrent glioblastomaAdverse eventsTherapy groupMedian progression-free survivalDevice-related adverse eventsSafety/feasibilitySerious adverse eventsFurther prospective studiesConcurrent therapyInvestigator's discretionStandard chemotherapyProspective studyTRIAL REGISTRATIONPatientsMonthsTreatmentHome-use deviceGlioblastomaWeeksSurvivalTotalGroup
2021
QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS
Blondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.Peer-Reviewed Original ResearchMalignant glioma patientsMedical marijuana programMalignant gliomasInactive patientsCannabis therapyActive patientsComplementary therapiesGlioma patientsOil supplementsCannabis productsMedian overall survivalSignificant palliative benefitSerious adverse eventsOverall survivalAdverse eventsDaily groupPalliative benefitCannabis treatmentPatientsPatient registration processOil groupTherapyGliomasMonthsSurvivalINNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA
Blondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.Peer-Reviewed Original ResearchYear old womanStable diseaseAnaplastic oligodendrogliomaOlder womenCycles of temozolomideRecurrent anaplastic oligodendrogliomaRecurrent glioblastoma patientsTemporal lobe gliosarcomaTreatment of gliosarcomaGlioma subtypesImproved survival outcomesSmall case seriesStandard of careRight frontal lobeConventional radiation therapyConcurrent temozolomideFurther chemotherapyRadiographic progressionOverall survivalCase seriesInitial diagnosisRadiographic findingsSurvival outcomesSignificant thrombocytopeniaHistorical controlsSurgical strategies for older patients with glioblastoma
Barak T, Vetsa S, Nadar A, Jin L, Gupte TP, Fomchenko EI, Miyagishima DF, Yalcin K, Vasandani S, Gorelick E, Zhao AY, Antonios J, Theriault BC, Lifton N, Marianayagam N, Omay B, Omay ZE, Huttner A, McGuone D, Blondin NA, Corbin Z, Fulbright RK, Moliterno J. Surgical strategies for older patients with glioblastoma. Journal Of Neuro-Oncology 2021, 155: 255-264. PMID: 34626296, PMCID: PMC8651607, DOI: 10.1007/s11060-021-03862-z.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreLength of surgeryOlder patientsOverall survivalPostoperative complicationsSurgical resectionSurgical strategyLow preoperative KPS scorePoor Karnofsky performance scoreLow Karnofsky performance scoreYale-New Haven HospitalPostoperative adjuvant treatmentPreoperative KPS scoreAdjuvant treatment regimensExtent of resectionNew Haven HospitalUse of ioMRIAdjuvant treatmentHospital stayKPS scoreMethodsClinical dataConsecutive patientsPrognostic factorsTreatment regimensExperienced hands
2019
ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.Peer-Reviewed Original ResearchSerious adverse eventsAdverse eventsRecurrent glioblastomaOverall survivalOutcome measuresDevice-related serious adverse eventsMedian overall survivalProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureLong-term treatmentMulti-center studyAnti-cancer therapyProspective studyTreatment groupsFeasible treatmentPatientsBrain cancerInvestigator's choiceInvestigational deviceChemotherapyGlioblastomaMonthsTreatmentACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.Peer-Reviewed Original ResearchAdverse eventsOutcome measuresDevice-related serious adverse eventsSerious adverse eventsProgression-free survivalSecondary outcome measuresCessation of treatmentFurther prospective studiesPrimary outcome measureStandard of careMulti-center studyMild dysesthesiaSurgical debulkingOverall survivalProspective studyClinical utilityFeasible treatmentPatientsBrain cancerInvestigational deviceMonthsTreatmentGBMSurvivalDebulking
2018
ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.Peer-Reviewed Original ResearchDevice-related adverse eventsAdverse eventsOutcome measuresMaximal tumor debulkingSecond-line therapyProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureStandard of careMulti-center trialInvestigational medical deviceTreatment of glioblastomaClinical utility dataContinual therapyConcurrent therapyOverall survivalProspective studySafety profileTumor debulkingInterim safetyClinical utilityFeasible treatmentPatientsBrain cancerQOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT
Blondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.Peer-Reviewed Original ResearchOverall survivalCannabis therapyTherapeutic cannabisPalliative useMedian ageCare treatmentGBM patientsSignificant adverse eventsTime period 2Time period 1Diagnosis dateAdverse eventsPatient ageSurvival benefitTumor characteristicsTherapeutic roleTreatment strategiesPatientsAnimal modelsHuman patientsGlioblastoma treatmentTherapeutic treatmentCannabis useTherapyGlioblastoma